MedTrace Logo

Clinical Behavior of the Asqelio™ Trifocal Diffractive Intraocular Lens

NCT05776446 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2023-03-20

No results posted yet for this study

Summary

The main objective of this study was to evaluate distance, intermediate, and near vision in patients who have undergone cataract extraction with bilateral implantation of a new hydrophobic trifocal diffractive intraocular lens (IOL) with a biospheric design, the Asqelio Trifocal IOL (AST Products, Inc., Billerica MA, USA), along with patient-reported outcomes (PRO). For that purpose the clinical information of 50 eyes from 25 patients was retrospectively analyzed 3 months after implantation

Conditions

  • Cataract

Sponsors & Collaborators

  • AST Products, Inc.

    lead INDUSTRY

Eligibility

Min Age
50 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-27
Primary Completion
2022-06-01
Completion
2022-09-01

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05776446 on ClinicalTrials.gov